• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Sanofi Genzyme Includes Vulnerable Kiwis in Their Compassionate Access Program

Sanofi Genzyme Includes Vulnerable Kiwis in Their Compassionate Access Program

by CAP | Feb 25, 2017 | Press Releases

Masterton, New Zealand – (February 25, 2017) – The New Zealand Pompe Network is ecstatic to announce that Sanofi Genzyme has offered Pompe disease patients in New Zealand access to their International Compassionate Access Program (ICAP) for the drug Myozyme®. A huge THANK YOU to Sanofi Genzyme for their generosity and their humanitarian program.

Recent Posts

  • Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
  • New Review Article Highlights Latest Developments in Pompe Disease Research
  • The Genetic Non-Discrimination Act
  • New ERT For Late-onset Pompe Disease Shows Promise
  • 2020 CAP Annual General Meeting
  • Terms
  • Privacy

Copyright © 2006 - 2021 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok